| Literature DB >> 34837958 |
Abbas Rezaianzadeh1, Esmaeil Khedmati Morasae2, Davood Khalili3, Mozhgan Seif4, Ehsan Bahramali5, Fereidoun Azizi6, Pezhman Bagheri7,8.
Abstract
BACKGROUND: Markov system dynamic (MSD) model has rarely been used in medical studies. The aim of this study was to evaluate the performance of MSD model in prediction of metabolic syndrome (MetS) natural history.Entities:
Keywords: Markov-system dynamics; Metabolic syndrome; Natural history
Mesh:
Substances:
Year: 2021 PMID: 34837958 PMCID: PMC8627615 DOI: 10.1186/s12874-021-01456-x
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.615
Fig. 1A 12-State dynamic transition diagram for MetS natural history
Fig. 2Causal loop and stock-flow diagrams for the no-component state
Fig. 3Causal loop and stock-flow diagrams for 1 and 2-component states
Fig. 4Causal loop and stock-flow diagrams for MetS state
Longitudinal change of MetS states among participants over the study period
| States of MetS | Baseline | F1 | F2 | F3 | F4 | Change (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Count | % | Count | % | Count | % | Count | % | Count | % | |||
| No Component | 1604 | 12.5 | 672 | 5.2 | 917 | 7.1 | 1154 | 9.0 | 1248 | 9.7 | − 22.1 | < 0.0001 |
| Isolated Overweight/Obesity | 1360 | 10.6 | 927 | 7.2 | 1370 | 10.6 | 2462 | 19.1 | 2725 | 21.2 | 100.3 | |
| Isolated Hypertension | 106 | .8 | 38 | .3 | 72 | .6 | 67 | .5 | 139 | 1.1 | 31.1 | |
| Isolated Dyslipidemia | 3902 | 30.3 | 2872 | 22.3 | 2112 | 16.4 | 1037 | 8.0 | 705 | 5.5 | − 81.9 | |
| Isolated Hyperglycemia | 143 | 1.1 | 96 | .7 | 279 | 2.2 | 303 | 2.4 | 456 | 3.5 | 218.8 | |
| Obesity + Hypertension | 233 | 1.8 | 128 | 1.0 | 131 | 1.0 | 284 | 2.2 | 508 | 3.9 | 118.0 | |
| Obesity + Dyslipidemia | 3325 | 25.8 | 4864 | 37.8 | 3767 | 29.2 | 3002 | 23.3 | 2017 | 15.7 | −39.3 | |
| Obesity + Hyperglycemia | 190 | 1.5 | 183 | 1.4 | 379 | 2.9 | 978 | 7.6 | 1192 | 9.3 | 527.3 | |
| Hypertension + Dyslipidemia | 264 | 2.0 | 190 | 1.5 | 178 | 1.4 | 94 | .7 | 97 | .8 | − 63.2 | |
| Hypertension + Hyperglycemia | 26 | .2 | 22 | .2 | 79 | .6 | 50 | .4 | 118 | .9 | 353.8 | |
| Dyslipidemia + Hyperglycemia | 350 | 2.7 | 538 | 4.2 | 737 | 5.7 | 351 | 2.7 | 333 | 2.6 | −4.8 | |
| MS | 1379 | 10.7 | 2352 | 18.3 | 2861 | 22.2 | 3100 | 24.1 | 3344 | 26.0 | 142.4 | |
*Two-sided p-value significance level = 0.05, and Cochrane test
Matrix of transition probabilities (%)
Fig. 5Risk of progression towards MetS for isolated components in Markov model
Fig. 6Risk of progression towards MetS for composite components in Markov model
Control and failure rates in metabolic syndrome interventions
| No component | 1-component | 2-component | MetS | ||
|---|---|---|---|---|---|
| Overall | CR | 36.66 | 62.29 | 77.37 | 43.94 |
| FR | 63.34 | 37.70 | 22.63 | – | |
Fig. 7Risk of progression towards MetS for isolated components in MSD model
Fig. 8Risk of progression towards MetS for composite components in MSD model